Advocacy intelligence hub — real-time data for patient organizations
Henry M. Jackson Foundation for the Advancement of Military Medicine — PHASE1
Children's Hospital Medical Center, Cincinnati — NA
National Institute of Allergy and Infectious Diseases (NIAID) — PHASE1
The University of Texas Health Science Center, Houston — NA
Massachusetts General Hospital — NA
University of California, San Diego — NA
Hennepin Healthcare Research Institute — PHASE4
Chinese University of Hong Kong — NA
Desmond Tutu HIV Foundation — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Biktarvy
Gilead Sciences
Patient Assistance Programs2
Viread
Gilead Sciences, Inc.
EBANGA�
Emergent Manufacturing Operations Baltimore LLC
EBANGA�
(ansuvimab-zykl)Orphan drugacceleratedEmergent Manufacturing Operations Baltimore LLC
Viread
(tenofovir)Orphan drugstandardGilead Sciences, Inc.
12.1 Mechanism of Action Tenofovir disoproxil fumarate is an antiviral drug [see Microbiology (12.4) ].
Retrovir
(zidovudine)Orphan drugstandardGlaxo Wellcome Inc.
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
12.1 Mechanism of Action Zidovudine is an antiretroviral agent [see Microbiology ( 12.4 )] .
Biktarvy
(bictegravir, emtricitabine, and tenofovir alafenamide)Orphan drugstandardGilead Sciences, Inc.
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
12.1 Mechanism of Action BIKTARVY is a fixed dose combination of antiretroviral drugs bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamid...
Myrielle Dupont-Rouzeyrol, PhD
Institut Pasteur de Nouvelle-Calédonie
Anna Durbin, MD
Johns Hopkins Bloomberg School of Public Health
📍 BALTIMORE, MD
Mario A Rojas, MD, MPH
Vanderbilt University
Matthew J Memoli, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Martin R Gaudinski, M.D., M.D
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Anna Durbin, M.D.
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
📍 BALTIMORE, MD